GSK has notified Alector that it is ending their immuno-neurology alliance, following major clinical setbacks for both investigational programs. The companies’ pact, struck in 2021 and scaled with amendments that shifted more development funding responsibility to Alector, covered two late-stage neurodegeneration candidates: latozinemab (AL001) and nivisnebart (AL101). Latozinemab failed to show meaningful benefit in a large late-stage study, while an interim futility analysis prompted Alector to discontinue its Phase 2 nivisnebart trial in early Alzheimer’s disease. GSK’s termination notice was issued July 6 and is expected to be fully settled by Jan. 2. The split marks a return attempt to brain diseases that GSK had deprioritized for more than a decade, including a parallel effort with the University of Oxford to create a drug-development center focused on Alzheimer’s, Parkinson’s and ALS.